Identification of several plasma proteins whose levels in colorectal cancer patients differ depending on outcome

Holm, Matilda; Joenväära, Sakari; Saraswat, Mayank; Mustonen, Harri; Tohmola, Tiialotta; Ristimäki, Ari; Renkonen, Risto; Haglund, Caj

doi:10.1096/fba.2019-00062

Cited by 9 publications

(9 citation statements)

References 35 publications

(65 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This data was confirmed by Western blot [218]. A high plasma level of MBP-C is a marker of poor survival for stage III CRC patients [171]. Using ELISA technique it was revealed that the MBP-C protein was significantly reduced in HCC cases [219].…”

Section: Mannose-binding Protein C (Mbl2_human)mentioning

confidence: 81%

“…The higher level of fetuin-B in plasma is correlated with a favorable outcome in the case of CRC [171].…”

Section: Fetuin-b (Fetub_human)mentioning

confidence: 97%

“…It is synthesized mainly in the liver and secreted into plasma where it converts cholesterol and phosphatidylcholines (lecithins) to cholesteryl esters and lysophosphatidylcholines on the surface of the high and low-density lipoproteins. High plasma levels of LCAT were correlated with a favorable outcome for patients with CRC [171]. Its precursor polypeptide chain has 440 AA, where AA 1-24 -the signal peptide, AA 25-440 -phosphatidylcholine-sterol acyltransferase (pI/Mw: 5.71/47084).…”

Section: Phosphatidylcholine-sterol Acyltransferase (Lcat_human)mentioning

confidence: 99%

“…PGRP-L is a pattern recognition receptor that is specifically expressed in the liver and implicated in the regulation of innate immunity and immunosurveillance. PGRP-L was down-regulated in plasma of patients with HCC or CRC, which was linked with poor prognosis in patients [171,221,222]. PGRP-L precursor polypeptide chain has 576 AA, where AA 1-21 -the signal peptide, AA 22-576 -PGRP-L (pI/Mw: 7.64/59980).…”

Section: N-acetylmuramoyl-l-alanine Amidase (Pgrp2_human)mentioning

confidence: 99%

See 3 more Smart Citations

Construction of 2DE-Patterns of Plasma Proteins: Aspect of Potential Tumor Markers

Naryzhny¹,

Ронжина²,

Zorina³

et al. 2022

Preprint

View full text Add to dashboard Cite

Cancer is a complex systemic disease that changes the entire proteome. The analysis of this transformation makes it possible to determine tumor markers, that is, the most characteristic biomacromolecules produced by tumor cells. Here, the question of finding ideal tumor markers, which should be sensitive, specific, and reliable, is an acute issue. Unfortunately, none of the tumor markers, even those used in the clinic, has all these characteristics. Despite this, many tumor markers have demonstrated excellent clinical relevance for monitoring the effectiveness of different treatments for cancer patients. The use of markers also aids in the early detection of cancer recurrence and prognosis. Therefore, the situation in this area can be improved in two ways – by attempting to find an ideal single tumor marker or generating panels of different markers. In both cases, proteomics certainly plays a major role. Human plasma is one of the most popular samples as it is commonly collected in the clinic and provides noninvasive, rapid analysis for any type of disease including cancer. Many efforts have been applied in searching for “ideal” tumor markers digging very deep plasma proteome. There is a line of evidence that the most abundant, so-called “classical plasma proteins”, may be used to generate a tumor biomarker profile. To be comprehensive these profiles should have information not only about protein levels but proteoform distribution for each protein. Initially, the profile of these proteins in norm should be generated. Here, we present data about these profiles generated by two-dimensional electrophoresis with the following mass-spectrometry and immunodetection.

show abstract

Section: Mannose-binding Protein C (Mbl2_human)mentioning

confidence: 81%

“…The higher level of fetuin-B in plasma is correlated with a favorable outcome in the case of CRC [171].…”

Section: Fetuin-b (Fetub_human)mentioning

confidence: 97%

Section: Phosphatidylcholine-sterol Acyltransferase (Lcat_human)mentioning

confidence: 99%

Section: N-acetylmuramoyl-l-alanine Amidase (Pgrp2_human)mentioning

confidence: 99%

See 2 more Smart Citations

Construction of 2DE-Patterns of Plasma Proteins: Aspect of Potential Tumor Markers

Naryzhny¹,

Ронжина²,

Zorina³

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…However, recent studies show controversial results. Holm et al showed that high plasma levels of MBL2 are a marker of poor survival in colorectal cancer patients [ 117 ]. Yitting et al reported that the MBL complement activation pathway is activated in patients with colorectal cancer compared with healthy controls; however, MBL pathway deficiency rates are similar between patients and healthy controls [ 118 ].…”

Section: Discussionmentioning

confidence: 99%

Plasma Proteome Signature to Predict the Outcome of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy

Gwark

Ahn

Yeom

et al. 2021

Cancers

View full text Add to dashboard Cite

The plasma proteome of 51 non-metastatic breast cancer patients receiving neoadjuvant chemotherapy (NCT) was prospectively analyzed by high-resolution mass spectrometry coupled with nano-flow liquid chromatography using blood drawn at the time of diagnosis. Plasma proteins were identified as potential biomarkers, and their correlation with clinicopathological variables and survival outcomes was analyzed. Of 51 patients, 20 (39.2%) were HR+/HER2-, five (9.8%) were HR+/HER2+, five (9.8%) were HER2+, and 21 (41.2%) were triple-negative subtype. During a median follow-up of 52.0 months, there were 15 relapses (29.4%) and eight deaths (15.7%). Four potential biomarkers were identified among differentially expressed proteins: APOC3 had higher plasma concentrations in the pathological complete response (pCR) group, whereas MBL2, ENG, and P4HB were higher in the non-pCR group. Proteins statistically significantly associated with survival and capable of differentiating low- and high-risk groups were MBL2 and P4HB for disease-free survival, P4HB for overall survival, and MBL2 for distant metastasis-free survival (DMFS). In the multivariate analysis, only MBL2 was a consistent risk factor for DMFS (HR: 9.65, 95% CI 2.10–44.31). The results demonstrate that the proteomes from non-invasive sampling correlate with pCR and survival in breast cancer patients receiving NCT. Further investigation may clarify the role of these proteins in predicting prognosis and thus their therapeutic potential for the prevention of recurrence.

show abstract

MORC protein family-related signature within human disease and cancer

et al. 2021

View full text Add to dashboard Cite

The microrchidia (MORC) family of proteins is a highly conserved nuclear protein superfamily, whose members contain common domain structures (GHKL-ATPase, CW-type zinc finger and coiled-coil domain) yet exhibit diverse biological functions. Despite the advancing research in previous decades, much of which focuses on their role as epigenetic regulators and in chromatin remodeling, relatively little is known about the role of MORCs in tumorigenesis and pathogenesis. MORCs were first identified as epigenetic regulators and chromatin remodelers in germ cell development. Currently, MORCs are regarded as disease genes that are involved in various human disorders and oncogenes in cancer progression and are expected to be the important biomarkers for diagnosis and treatment. A new paradigm of expanded MORC family function has raised questions regarding the regulation of MORCs and their biological role at the subcellular level. Here, we systematically review the progress of researching MORC members with respect to their domain architectures, diverse biological functions, and distribution characteristics and discuss the emerging roles of the aberrant expression or mutation of MORC family members in human disorders and cancer development. Furthermore, the illustration of related mechanisms of the MORC family has made MORCs promising targets for developing diagnostic tools and therapeutic treatments for human diseases, including cancers.

show abstract

Identification of several plasma proteins whose levels in colorectal cancer patients differ depending on outcome

Cited by 9 publications

References 35 publications

Construction of 2DE-Patterns of Plasma Proteins: Aspect of Potential Tumor Markers

Construction of 2DE-Patterns of Plasma Proteins: Aspect of Potential Tumor Markers

Plasma Proteome Signature to Predict the Outcome of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy

MORC protein family-related signature within human disease and cancer

Contact Info

Product

Resources

About